Follow Us:
Pegloticase Exporter From India

Pegloticase

Pegloticase is a medication used for the treatment of chronic gout in adults with severe, uncontrolled gout that does not respond adequately to conventional therapies. It belongs to the uricase enzyme replacement therapy class of drugs. It works by converting uric acid into allantoin, a more water-soluble substance that can be easily eliminated through urine. This helps reduce high uric acid levels in the blood and dissolve urate crystal deposits in joints and tissues. Pegloticase is administered through intravenous infusion, usually every two weeks. Common side effects include nausea, gout flare-ups, and infusion-site reactions. Serious adverse effects may include severe allergic reactions (anaphylaxis), infusion reactions, and haemolysis in patients with G6PD deficiency. It should be administered under strict medical supervision with appropriate monitoring.

  • Dosage Form:
  • Dosage Strength:
  • Manufacturer:
  • CAS No.:
  • Status:

Applications of Pegloticase

Pegloticase was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:

is okay

Contraindication of Pegloticase

Availability of Pegloticase

Delivery of Pegloticase

Frequently Asked Questions

The most frequently asked questions focus on import, export, documentations, and regulation for Pegloticase.

The is a pharmaceutical active pharmaceutical ingredient (API) used in manufacturing of Pegloticase.

: Provides active pharmaceutical ingredients (APIs), customized production, and OEM/ODM services with research and technical cooperation across Europe, the USA, and India via Primeera Healthcare.

  • Therapeutic Goods Administration (TGA):
  • US Food and Drug Administration (USFDA):
  • European Medicines Agency (EMA):
  • African Medicines Agency (AMA):
  • National Medical Products Administration (NMPA):
  • Central Drugs Standard Control Organization (CDSCO):

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Pegloticase, subject to confirmation of its current regulatory status and eligibility for import into India.

Documentation Required for Pegloticase Import

The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.

Import Regulations and dcoumentation for Pegloticase

  • Import Documentation Assistance:
    Support with organising commercial invoices, packing lists, manufacturer details, product specifications, certificates of analysis, and other relevant documents required for regulatory review and customs processing.

  • Regulatory Coordination:
    Assistance with identifying applicable CDSCO requirements, import authorisations, and documentation procedures, subject to the product's regulatory status and the proposed import route.
  • Shipping and Customs Coordination:
    Coordination with relevant logistics providers and customs professionals to organise shipment documentation and facilitate clearance where legally permitted.
  • Compliance Verification:
    Preliminary review of available product and shipment documentation to identify potential regulatory gaps before procurement or dispatch. Import arrangements will proceed only after the applicable permissions and restrictions have been verified.

Customs Clearance and Compliance Handling of Pegloticase Import

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Pegloticase, subject to confirmation of its current regulatory status and eligibility for import into India.

Export Regulations and dcoumentation for Pegloticase

The export of Pegloticase from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.

Documentation Required for Pegloticase Emport

  • Export Documentation Assistance:
    Assistance with organising commercial invoices, packing lists, manufacturer details, Pegloticase specifications, certificates of analysis, and other supporting documents required for Pegloticase export and customs processing.
  • Regulatory Coordination:
    Support in identifying applicable country specific Pegloticase export requirements, relevant manufacturing and export authorisations, and destination-country registration or import approval requirements, subject to the Pegloticase regulatory status.
  • Shipping and Customs Coordination:
    Coordination with logistics providers, freight forwarders, and customs professionals to organise shipping documentation, export declarations, and customs clearance procedures where legally permitted.
  • Compliance Verification:
    Preliminary review of available Pegloticase documentation, labelling, Pegloticase manufacturing information, and destination-market requirements to identify potential regulatory gaps before dispatch. Export arrangements will proceed only after the applicable restrictions and authorisations have been verified.

Customs Clearance and Compliance Handling of Pegloticase Export

Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Pegloticase, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.

Product Export Support

If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.

Disclaimer

All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.